发明申请
WO2022238386A1 METHODS FOR THE TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES
审中-公开
基本信息:
- 专利标题： METHODS FOR THE TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES
- 申请号：PCT/EP2022/062607 申请日：2022-05-10
- 公开(公告)号：WO2022238386A1 公开(公告)日：2022-11-17
- 发明人： THERY, Clotilde , TKACH, Mercedes
- 申请人： INSTITUT CURIE , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
- 申请人地址： 26 rue d'Ulm; 101, rue de Tolbiac
- 专利权人： INSTITUT CURIE,INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
- 当前专利权人： INSTITUT CURIE,INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
- 当前专利权人地址： 26 rue d'Ulm; 101, rue de Tolbiac
- 代理机构： PLASSERAUD IP
- 优先权： EP21305600.5 2021-05-10
- 主分类号： C12N5/0786
- IPC分类号： C12N5/0786 ; A61K35/13 ; A61K35/15 ; A61P35/00 ; A61K39/00 ; A61P29/00 ; A61P37/02 ; A61K2039/5154 ; A61K38/193 ; A61K39/0011 ; C07K14/00 ; C12N2502/30 ; C12N5/0645
摘要：
The invention relates to methods and pharmaceutical compositions for the treatment and diagnosis of cancer. The invention also relates to methods and pharmaceutical compositions for the treatment of inflammatory diseases and autoimmune diseases. The inventors investigate the role and specific contribution of extracellular vesicles (EVs) in cancer environment. The inventors demonstrate that CSF1 -associated EVs induce macrophage signature associated with T cell infiltration and extended patient survival. The inventors demonstrate that via specific extracellular vesicles, these tumors promote pro-inflammatory macrophages correlated with better clinical outcome and a better prognosis in TNBC patients. In the present invention, the inventors provide in vitro evidences towards a direct role of CSF1 -associated EVs as tools, alone or with other immuno-therapies, to promote anti-tumor immune responses. Thus, the present invention relates to CSF1 -associated EVs, their use in the treatment and diagnosis of cancer, and their targeting in the treatment of inflammatory diseases and autoimmune diseases.